Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Revuforj (revumenib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Syndax Pharma

Drug class:

Menin-MLL inhibitor

Related drugs:

‹

ziftomenib (13)

ziftomenib (13)

›

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2
KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: C3 – Early Trials revumenib Sensitive : C3	revumenib Sensitive: C3 – Early Trials revumenib Sensitive : C3
NUP98 rearrangement	Acute Myelogenous Leukemia	NUP98 rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3
NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	revumenib Sensitive: D – Preclinical revumenib Sensitive : D	revumenib Sensitive: D – Preclinical revumenib Sensitive : D
NPM1 expression	Acute Myelogenous Leukemia	NPM1 expression	Acute Myelogenous Leukemia	revumenib Sensitive: D – Preclinical revumenib Sensitive : D	revumenib Sensitive: D – Preclinical revumenib Sensitive : D
KMT2A expression	Acute Myelogenous Leukemia	KMT2A expression	Acute Myelogenous Leukemia	revumenib Sensitive: D – Preclinical revumenib Sensitive : D	revumenib Sensitive: D – Preclinical revumenib Sensitive : D